Medical Device Manufacturing - Insulin Delivery Systems & Diabetes Technology
Strategic Profile
Tandem is the number one recommended insulin pump brand by people living with diabetes for multiple years, having established significant brand loyalty and trust. The company leverages interoperable technology with major CGM manufacturers like Dexcom and Abbott, positioning itself as a comprehensive diabetes management platform rather than a standalone device maker.
Cyborg Score Rationale
Tandem's 2024 revenue was $940.20 million, an increase of 25.74% compared to the previous year's $747.72 million. The company is demonstrating strong market traction with profitable operations and continued product innovation. However, modest market cap and scale relative to larger medtech peers temper the outlook.
Top Insights
Rapid revenue growth of 25.7% YoY in 2024 signals strong market adoption of automated insulin delivery systems
Tandem Mobi launched in February 2024 as "world's smallest durable automated insulin delivery system" with European rollout planned by end of 2025, expanding addressable market
Control-IQ+ technology now cleared for both type 1 and type 2 diabetes (ages 2+/18+ respectively), significantly broadening patient population
Strategic integrations with Dexcom G6/G7 CGMs and Abbott FreeStyle Libre sensors create ecosystem moat and increase switching costs
Named Competitors
Guardian 4 Continuous Glucose Monitor / MiniMed 7xx Pumps — Largest insulin pump manufacturer with dominant market share
Omnipod 5 — Tubeless wearable insulin pump with interoperable technology
Automated Insulin Delivery Systems — Next-generation artificial pancreas technology platform
Recent Developments
(February 2026) t:slim mobile app authorized in Canada for iPhone and Android devices
(November 2025) ISO/IEC 27001:2022 certification achieved for information security management
(2024) Tandem Mobi system commercial launch in US; European expansion planned for 2025
(2024) Control-IQ+ algorithm FDA clearance expanded to include type 2 diabetes patients
Open the full interactive Tandem Diabetes Care, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.